Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur in >40% of cases.Here, we studied the molecular mechanisms underlying refractory/relapsed (R/R) dise